Amylyx Pharmaceuticals, Inc. (AMLX)

$2

-0.01

(-0.5%)▲

Market is closed - opens 7 PM, 18 Apr 2024

Insights on Amylyx Pharmaceuticals, Inc.

  • Increasing Revenue

    Revenue is up for the last 7 quarters, 285.0K → 108.44M (in $), with an average increase of 37.0% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 3 quarters, 22.07M → 4.73M (in $), with an average decrease of 41.4% per quarter

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 44.3% return, outperforming this stock by 137.8%

Performance

  • $1.99
    $2.08
    $2.00
    downward going graph

    0.5%

    Downside

    Day's Volatility :4.33%

    Upside

    3.85%

    downward going graph
  • $1.98
    $31.77
    $2.00
    downward going graph

    1.0%

    Downside

    52 Weeks Volatility :93.77%

    Upside

    93.7%

    downward going graph

Returns

PeriodAmylyx Pharmaceuticals, Inc.Sector (Health Care)Index (Russel 2000)
3 Months
-86.67%
-0.5%
0.0%
6 Months
-88.76%
5.9%
0.0%
1 Year
-93.48%
3.1%
-1.9%
3 Years
-88.88%
14.2%
-21.8%

Highlights

Market Capitalization
140.6M
Book Value
$6.52
Earnings Per Share (EPS)
0.7
PE Ratio
2.87
Wall Street Target Price
4.25
Profit Margin
12.94%
Operating Margin TTM
1.78%
Return On Assets TTM
5.34%
Return On Equity TTM
12.73%
Revenue TTM
380.8M
Revenue Per Share TTM
5.66
Quarterly Revenue Growth YOY
395.5%
Gross Profit TTM
-74.2M
EBITDA
39.9M
Diluted Eps TTM
0.7
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-1.6
EPS Estimate Next Year
-0.77
EPS Estimate Current Quarter
0.23
EPS Estimate Next Quarter
0.28

Analyst Recommendation

Buy
    91%Buy
    8%Hold
    0
    0%Sell
Based on 12 Wall street analysts offering stock ratings for Amylyx Pharmaceuticals, Inc.(by analysts ranked 0 to 5 stars)
Based on 12 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
11
11
12
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 112.5%

Current $2.00
Target $4.25

Company Financials

FY19Y/Y Change
Revenue
1.4M
-
Net Income
-14.8M
-
Net Profit Margin
-1.0K%
-
FY20Y/Y Change
Revenue
650.0K
↓ 54.42%
Net Income
-44.8M
↑ 202.63%
Net Profit Margin
-6.9K%
↓ 5859.01%
FY21Y/Y Change
Revenue
285.0K
↓ 56.15%
Net Income
-87.9M
↑ 96.0%
Net Profit Margin
-30.8K%
↓ 23936.74%
FY22Y/Y Change
Revenue
22.2M
↑ 7700.0%
Net Income
-198.4M
↑ 125.74%
Net Profit Margin
-892.38%
↑ 29942.36%
FY23Y/Y Change
Revenue
380.8M
↑ 1612.94%
Net Income
49.3M
↓ 124.84%
Net Profit Margin
12.94%
↑ 905.32%
Q3 FY22Q/Q Change
Revenue
345.0K
-
Net Income
-53.8M
↓ 0.58%
Net Profit Margin
-15.6K%
-
Q4 FY22Q/Q Change
Revenue
21.9M
↑ 6243.48%
Net Income
-42.7M
↓ 20.56%
Net Profit Margin
-195.13%
↑ 15386.32%
Q1 FY23Q/Q Change
Revenue
71.4M
↑ 226.38%
Net Income
1.6M
↓ 103.68%
Net Profit Margin
2.2%
↑ 197.33%
Q2 FY23Q/Q Change
Revenue
98.2M
↑ 37.5%
Net Income
22.1M
↑ 1303.31%
Net Profit Margin
22.47%
↑ 20.27%
Q3 FY23Q/Q Change
Revenue
102.7M
↑ 4.56%
Net Income
20.9M
↓ 5.35%
Net Profit Margin
20.35%
↓ 2.12%
Q4 FY23Q/Q Change
Revenue
108.4M
↑ 5.61%
Net Income
4.7M
↓ 77.36%
Net Profit Margin
4.36%
↓ 15.99%
FY19Y/Y Change
Total Assets
3.2M
-
Total Liabilities
28.6M
-
FY20Y/Y Change
Total Assets
14.1M
↑ 338.01%
Total Liabilities
80.8M
↑ 182.85%
FY21Y/Y Change
Total Assets
105.6M
↑ 648.82%
Total Liabilities
256.8M
↑ 217.69%
FY22Y/Y Change
Total Assets
391.5M
↑ 270.64%
Total Liabilities
50.8M
↓ 80.2%
FY23Y/Y Change
Total Assets
517.5M
↑ 32.19%
Total Liabilities
84.0M
↑ 65.25%
Q3 FY22Q/Q Change
Total Assets
181.4M
↓ 19.44%
Total Liabilities
37.4M
↑ 15.3%
Q4 FY22Q/Q Change
Total Assets
391.5M
↑ 115.74%
Total Liabilities
50.8M
↑ 35.9%
Q1 FY23Q/Q Change
Total Assets
408.0M
↑ 4.22%
Total Liabilities
55.3M
↑ 8.78%
Q2 FY23Q/Q Change
Total Assets
453.6M
↑ 11.18%
Total Liabilities
67.2M
↑ 21.54%
Q3 FY23Q/Q Change
Total Assets
466.6M
↑ 2.87%
Total Liabilities
48.2M
↓ 28.32%
Q4 FY23Q/Q Change
Total Assets
517.5M
↑ 10.9%
Total Liabilities
84.0M
↑ 74.38%
FY19Y/Y Change
Operating Cash Flow
-10.7M
-
Investing Cash Flow
-151.0K
-
Financing Cash Flow
668.0K
-
FY20Y/Y Change
Operating Cash Flow
-36.7M
↑ 243.38%
Investing Cash Flow
-151.0K
↑ 0.0%
Financing Cash Flow
46.8M
↑ 6909.43%
FY21Y/Y Change
Operating Cash Flow
-74.8M
↑ 103.83%
Investing Cash Flow
-46.4M
↑ 30632.45%
Financing Cash Flow
158.5M
↑ 238.52%
FY22Y/Y Change
Operating Cash Flow
-179.9M
↑ 140.47%
Investing Cash Flow
-239.0M
↑ 414.99%
Financing Cash Flow
431.8M
↑ 172.41%
Q3 FY22Q/Q Change
Operating Cash Flow
-43.1M
↓ 7.28%
Investing Cash Flow
84.0M
↑ 1783.48%
Financing Cash Flow
199.6M
↓ 24209.54%
Q4 FY22Q/Q Change
Operating Cash Flow
-49.7M
↑ 15.37%
Investing Cash Flow
-228.2M
↓ 371.51%
Financing Cash Flow
232.2M
↑ 16.3%
Q1 FY23Q/Q Change
Operating Cash Flow
-5.1M
↓ 89.79%
Investing Cash Flow
56.0M
↓ 124.54%
Financing Cash Flow
1.0M
↓ 99.55%
Q2 FY23Q/Q Change
Operating Cash Flow
8.6M
↓ 269.74%
Investing Cash Flow
123.2M
↑ 120.06%
Financing Cash Flow
1.4M
↑ 33.08%

Technicals Summary

Sell

Neutral

Buy

Amylyx Pharmaceuticals, Inc. is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Amylyx Pharmaceuticals, Inc.
Amylyx Pharmaceuticals, Inc.
-29.72%
-88.76%
-93.48%
-88.88%
-88.88%
Moderna, Inc.
Moderna, Inc.
-0.45%
20.22%
-27.91%
-35.9%
341.66%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-6.85%
6.85%
9.08%
78.94%
160.71%
Novo Nordisk A/s
Novo Nordisk A/s
-7.1%
22.03%
44.33%
239.61%
408.97%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-4.18%
5.53%
20.27%
79.84%
136.07%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Amylyx Pharmaceuticals, Inc.
Amylyx Pharmaceuticals, Inc.
2.87
2.87
NA
-1.6
0.13
0.05
NA
6.52
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.21
-0.29
-0.12
NA
36.27
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
25.84
25.84
1.46
45.15
0.16
0.08
NA
242.47
Novo Nordisk A/s
Novo Nordisk A/s
46.75
46.75
2.4
3.36
0.88
0.23
0.01
23.9
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
28.57
28.57
0.53
16.72
0.23
0.13
NA
68.22
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Amylyx Pharmaceuticals, Inc.
Amylyx Pharmaceuticals, Inc.
Buy
$140.6M
-88.88%
2.87
12.94%
Moderna, Inc.
Moderna, Inc.
Buy
$40.3B
341.66%
24.73
-68.84%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$98.6B
160.71%
25.84
30.14%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$559.8B
408.97%
46.75
36.03%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$102.7B
136.07%
28.57
36.68%

Institutional Holdings

  • Vanguard Group Inc

    7.78%

  • BlackRock Inc

    5.90%

  • Viking Global Investors LP

    4.37%

  • Morgan Stanley - Brokerage Accounts

    4.18%

  • Goldman Sachs Group Inc

    3.71%

  • Stonepine Capital Management Llc

    3.69%

Company Information

Amylyx Pharmaceuticals, Inc is a biopharmaceutical company headquartered in Cambridge, Massachusetts. Amylyx is best known for AMX0035, an experimental therapy for amyotrophic lateral sclerosis.

Organization
Amylyx Pharmaceuticals, Inc.
Employees
384
CEO
Mr. Joshua B. Cohen
Industry
Services

Discover More

FAQs